MedtechInvest 2025 Program Overview

MedtechInvest 2025 brings together investors, medtech innovators, and industry leaders for a full day of keynotes, panel discussions, and company showcases, offering critical insights into the evolving medtech investment landscape.

This year’s program will explore:

• The evolving medtech investment landscape:  A deep dive into capital flows, shifting market dynamics, and the key drivers of investor confidence in 2025.
• The role of intellectual property in investment success: How robust IP strategies enhance company valuation, mitigate risk, and create a competitive advantage.
• Global market insights and medtech trends:  An analysis of the latest trends and market conditions shaping the future of medtech.
• Investment-ready company showcases: Featuring 12 medtech companies with groundbreaking innovations, connecting capital with the technologies set to transform healthcare.

MedtechInvest Speakers

Dr. Nicholas Pachuda

General Partner, Neovate Capital

Chief Operating Officer, Peptilogics

Co-founder and Operating Partner, Precision Life Science Partners

Dr. Nicholas Pachuda is a seasoned life science professional who accelerates transformational technologies to the clinic globally.  He is the Chief Operating Officer at Peptilogics, a General Partner at Neovate Capital, an early-stage venture fund, and a Co-Founder and Operating Partner at Precision Life Science Partners, a boutique startup and investor advisory company.  He serves on several boards of Medtech startups and is chairman of one.  Previously, he has held executive roles in business development, commercial business/P&L leadership, R&D, clinical development, and portfolio strategy. Dr. Pachuda's leadership was pivotal in the success of two startups (Small Bone Innovations exit to Stryker and Scient’x Spine exit to Alphatec) and three multinationals, including a decade at J&J, where he led Global External Innovation. His strategic vision and innovative thinking were evident in the foundational investments/acquisitions of J&J’s robotics, anti-infection, and regenerative medicine businesses. Dr. Pachuda co-founded the extremities business at Arthrex ($1B global revenue today) and led M&A and new ventures for Synthes, where he launched their first ambulatory surgery center business. His professional background includes training as a Foot and Ankle Surgeon and completing an International Orthopedic Trauma Fellowship.

Kylie Frazer

Kylie Frazer is reshaping early-stage investing in Australia as co-founding partner of Flying Fox Ventures, one of the country's most active early-stage investment firms with over 60 investments in cutting-edge technology companies. A founder twice over and former corporate transactions lawyer, Kylie brings unique perspective from both sides of the investment table. She currently serves as Investor in Residence at UNSW, where she delivers the Angel Investor Program and works to deliver world class outcomes for portfolio companies across the Health, Climate and Defence streams. Kylie also serves on the Investment Committee of Beanstalk’s Drought Venture Studio, working to tackle critical climate challenges.

Elyse Shapiro

Elyse is the Australian healthcare analyst for Canaccord Genuity. She provides unique insights into biotech, medtech, services, and diagnostics companies. She has 10 years’ experience covering biotechnology, starting from Cowen in NYC.